EXACT Sciences Corporation Unveils Latest Presentation on Advanced Cancer Diagnostics and New Test Launches
EXACT Sciences Corporation has shared its latest corporate presentation, highlighting its role as a global leader in advanced cancer diagnostics with a focus on expanding its capabilities. The company successfully launched three new advanced cancer tests in 2025: Cologuard Plus for colon cancer screening in March, Oncodetect for molecular residual disease in April, and Cancerguard for multi-cancer screening in September. These tests target substantial total addressable markets of $18 billion, $15 billion, and $25 billion respectively. The company reported $811 million in total revenue for the second quarter of 2025, reflecting a 16% year-over-year increase, alongside an adjusted EBITDA of $138 million, up 26% year-over-year. With over 7,000 global team members, 200,000+ ordering providers each quarter, and nine R&D centers and labs, EXACT Sciences continues to deliver over 1.3 million test results in the second quarter of 2025. The company's proprietary scientific platform aims to detect cancer earlier and accurately, supported by its robust commercial engine and ExactNexus technology platform. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.